BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) released its earnings results on Thursday. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.61, Briefing.com reports. The firm had revenue of $2.17 million during the quarter, compared to analyst estimates of $3.96 million. During the same quarter last year, the business posted ($0.98) EPS. The firm’s revenue was up 32.1% on a year-over-year basis.
BridgeBio Pharma Price Performance
Shares of NASDAQ:BBIO remained flat at $26.18 during trading on Friday. 1,415,727 shares of the stock were exchanged, compared to its average volume of 1,332,450. BridgeBio Pharma has a 12 month low of $21.62 and a 12 month high of $44.32. The stock has a market capitalization of $4.90 billion, a price-to-earnings ratio of -8.13 and a beta of 1.06. The firm’s 50 day moving average is $26.74 and its two-hundred day moving average is $29.33.
Insider Transactions at BridgeBio Pharma
In other BridgeBio Pharma news, Director Randal W. Scott sold 1,000 shares of BridgeBio Pharma stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $28.84, for a total transaction of $28,840.00. Following the sale, the director now owns 5,500 shares in the company, valued at $158,620. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 24.66% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on BridgeBio Pharma
About BridgeBio Pharma
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Featured Stories
- Five stocks we like better than BridgeBio Pharma
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Consumer Staples Stocks, Explained
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What is Put Option Volume?
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.